The Lancet1d
Alcohol and cancer risk: bridging the awareness gap
Each year in the USA, alcohol use contributes to nearly 100 000 new cancer cases and 20 000 deaths from cancer, according to ...
oncnursingnews1d
Amezalpat Receives FDA Fast Track Designation for Hepatocellular Carcinoma
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
A Promising Development for Millions of People With Liver Disease
Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...